Therapeutic vaccination against human papilloma virus induced malignancies (Q37828885)

24 August 2017

1 reference

title

Therapeutic vaccination against human papilloma virus induced malignancies (English)

1 reference

24 August 2017

1 reference

human papilloma virus

object named as

human papilloma virus

1 reference

based on heuristic

inferred from title

author

Cornelis J. M. Melief

2

object named as

Cornelis J M Melief

1 reference

24 August 2017

Sjoerd H van der Burg

1

object named as

Sjoerd H van der Burg

1 reference

24 August 2017

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=21237632

22 November 2024

publication date

13 January 2011

1 reference

full work available at URL

24 August 2017

https://api.elsevier.com/content/article/PII:S0952791510002128?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/J.COI.2010.12.010

https://api.elsevier.com/content/article/PII:S0952791510002128?httpAccept=text/plain

22 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.COI.2010.12.010

Current Opinion in Immunology

22 November 2024

published in

1 reference

24 August 2017

volume

23

1 reference

24 August 2017

issue

2

1 reference

24 August 2017

page(s)

252-257

1 reference

Evolving immunosuppressive microenvironment during human cervical carcinogenesis

24 August 2017

cites work

1

1 reference

https://api.crossref.org/works/10.1016/J.COI.2010.12.010

Diminished IFN-gamma and IL-10 and elevated Foxp3 mRNA expression in the cervix are associated with CIN 2 or 3.

22 November 2024

2

1 reference

https://api.crossref.org/works/10.1016/J.COI.2010.12.010

Immunosuppressive cytokine Interleukin-10 (IL-10) is up-regulated in high-grade CIN but not associated with high-risk human papillomavirus (HPV) at baseline, outcomes of HR-HPV infections or incident CIN in the LAMS cohort

22 November 2024

3

1 reference

https://api.crossref.org/works/10.1016/J.COI.2010.12.010

High Number of Intraepithelial CD8 Tumor-Infiltrating Lymphocytes Is Associated with the Absence of Lymph Node Metastases in Patients with Large Early-Stage Cervical Cancer

22 November 2024

4

1 reference

https://api.crossref.org/works/10.1016/J.COI.2010.12.010

Assessment of cytotoxic T-lymphocyte phenotype using the specific markers granzyme B and TIA-1 in cervical neoplastic lesions

22 November 2024

5

1 reference

https://api.crossref.org/works/10.1016/J.COI.2010.12.010

Tumor-Expressed B7-H1 and B7-DC in Relation to PD-1 T-Cell Infiltration and Survival of Patients with Cervical Carcinoma

22 November 2024

6

1 reference

https://api.crossref.org/works/10.1016/J.COI.2010.12.010

Correlation of CXCL12 expression and FoxP3 cell infiltration with human papillomavirus infection and clinicopathological progression of cervical cancer.

22 November 2024

7

1 reference

https://api.crossref.org/works/10.1016/J.COI.2010.12.010

Macrophages, inflammation and risk of cervical intraepithelial neoplasia (CIN) progression--clinicopathological correlation

22 November 2024

8

1 reference

https://api.crossref.org/works/10.1016/J.COI.2010.12.010

FOXP3 defines regulatory T cells in human tumor and autoimmune disease

22 November 2024

9

1 reference

https://api.crossref.org/works/10.1016/J.COI.2010.12.010

Indoleamine 2,3-dioxygenase and tumor-induced tolerance

22 November 2024

10

1 reference

https://api.crossref.org/works/10.1016/J.COI.2010.12.010

HPV16 tumor associated macrophages suppress antitumor T cell responses.

22 November 2024

11

1 reference

https://api.crossref.org/works/10.1016/J.COI.2010.12.010

The absence of CCL2 expression in cervical carcinoma is associated with increased survival and loss of heterozygosity at 17q11.2.

22 November 2024

12

1 reference

https://api.crossref.org/works/10.1016/J.COI.2010.12.010

Metastatic tumour cells favour the generation of a tolerogenic milieu in tumour draining lymph node in patients with early cervical cancer.

22 November 2024

13

1 reference

https://api.crossref.org/works/10.1016/J.COI.2010.12.010

Characterising the local immune responses in cervical intraepithelial neoplasia: a cross-sectional and longitudinal analysis

22 November 2024

14

1 reference

https://api.crossref.org/works/10.1016/J.COI.2010.12.010

Human leukocyte antigen class I, MHC class I chain-related molecule A, and CD8 /regulatory T-cell ratio: which variable determines survival of cervical cancer patients?

22 November 2024

16

1 reference

https://api.crossref.org/works/10.1016/J.COI.2010.12.010

Elevated expression of SerpinA1 and SerpinA3 in HLA-positive cervical carcinoma

22 November 2024

17

1 reference

https://api.crossref.org/works/10.1016/J.COI.2010.12.010

A prospective study on the natural course of low-grade squamous intraepithelial lesions and the presence of HPV16 E2-, E6- and E7-specific T-cell responses

22 November 2024

18

1 reference

https://api.crossref.org/works/10.1016/J.COI.2010.12.010

Cell-mediated immune responses to human papillomavirus 16 E6 and E7 antigens as measured by interferon gamma enzyme-linked immunospot in women with cleared or persistent human papillomavirus infection

22 November 2024

19

1 reference

https://api.crossref.org/works/10.1016/J.COI.2010.12.010

Surgery followed by Persistence of High-Grade Squamous Intraepithelial Lesions Is Associated with the Induction of a Dysfunctional HPV16-Specific T-Cell Response

22 November 2024

20

1 reference

https://api.crossref.org/works/10.1016/J.COI.2010.12.010

Naturally occurring systemic immune responses to HPV antigens do not predict regression of CIN2/3

22 November 2024

21

1 reference

https://api.crossref.org/works/10.1016/J.COI.2010.12.010

IFN-gamma produced by human papilloma virus-18 E6-specific CD4 T cells predicts the clinical outcome after surgery in patients with high-grade cervical lesions

22 November 2024

22

1 reference

https://api.crossref.org/works/10.1016/J.COI.2010.12.010

Human papillomavirus 16-specific T cell responses in classic HPV-related vulvar intra-epithelial neoplasia. Determination of strongly immunogenic regions from E6 and E7 proteins

22 November 2024

23

1 reference

https://api.crossref.org/works/10.1016/J.COI.2010.12.010

Detection of human papillomavirus (HPV) 16-specific CD4 T-cell immunity in patients with persistent HPV16-induced vulvar intraepithelial neoplasia in relation to clinical impact of imiquimod treatment

22 November 2024

24

1 reference

https://api.crossref.org/works/10.1016/J.COI.2010.12.010

Human papilloma virus specific T cells infiltrating cervical cancer and draining lymph nodes show remarkably frequent use of HLA-DQ and -DP as a restriction element.

22 November 2024

25

1 reference

https://api.crossref.org/works/10.1016/J.COI.2010.12.010

An Unexpectedly Large Polyclonal Repertoire of HPV-Specific T Cells Is Poised for Action in Patients with Cervical Cancer

22 November 2024

26

1 reference

https://api.crossref.org/works/10.1016/J.COI.2010.12.010

Association of cervical cancer with the presence of CD4 regulatory T cells specific for human papillomavirus antigens.

22 November 2024

27

1 reference

https://api.crossref.org/works/10.1016/J.COI.2010.12.010

Increase of human papillomavirus-16 E7-specific T helper type 1 response in peripheral blood of cervical cancer patients after radiotherapy

22 November 2024

29

1 reference

https://api.crossref.org/works/10.1016/J.COI.2010.12.010

Treatment of vulvar intraepithelial neoplasia with topical imiquimod

22 November 2024

30

1 reference

https://api.crossref.org/works/10.1016/J.COI.2010.12.010

Imiquimod-induced clearance of HPV is associated with normalization of immune cell counts in usual type vulvar intraepithelial neoplasia

22 November 2024

31

1 reference

https://api.crossref.org/works/10.1016/J.COI.2010.12.010

Clinical and immunologic results of a phase II trial of sequential imiquimod and photodynamic therapy for vulval intraepithelial neoplasia

22 November 2024

32

1 reference

https://api.crossref.org/works/10.1016/J.COI.2010.12.010

Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia

22 November 2024

33

1 reference

https://api.crossref.org/works/10.1016/J.COI.2010.12.010

Success or failure of vaccination for HPV16-positive vulvar lesions correlates with kinetics and phenotype of induced T-cell responses

22 November 2024

34

1 reference

https://api.crossref.org/works/10.1016/J.COI.2010.12.010

Phase II trial of imiquimod and HPV therapeutic vaccination in patients with vulval intraepithelial neoplasia

22 November 2024

35

1 reference

https://api.crossref.org/works/10.1016/J.COI.2010.12.010

CD4 CD25 regulatory T cells control T helper cell type 1 responses to foreign antigens induced by mature dendritic cells in vivo

22 November 2024

36

1 reference

https://api.crossref.org/works/10.1016/J.COI.2010.12.010

CD8( ) T lymphocyte mobilization to virus-infected tissue requires CD4( ) T-cell help

22 November 2024

37

1 reference

https://api.crossref.org/works/10.1016/J.COI.2010.12.010

Human papillomavirus type 16 and 18 E7-pulsed dendritic cell vaccination of stage IB or IIA cervical cancer patients: a phase I escalating-dose trial.

22 November 2024

38

1 reference

https://api.crossref.org/works/10.1016/J.COI.2010.12.010

Phase I Immunotherapeutic Trial with Long Peptides Spanning the E6 and E7 Sequences of High-Risk Human Papillomavirus 16 in End-Stage Cervical Cancer Patients Shows Low Toxicity and Robust Immunogenicity

22 November 2024

39

1 reference

https://api.crossref.org/works/10.1016/J.COI.2010.12.010

Induction of Tumor-Specific CD4 and CD8 T-Cell Immunity in Cervical Cancer Patients by a Human Papillomavirus Type 16 E6 and E7 Long Peptides Vaccine

22 November 2024

40

1 reference

https://api.crossref.org/works/10.1016/J.COI.2010.12.010

Local accumulation of FOXP3 regulatory T cells: evidence for an immune evasion mechanism in patients with large condylomata acuminata

22 November 2024

41

1 reference

https://api.crossref.org/works/10.1016/J.COI.2010.12.010

Selective depletion of CD4 CD25 Foxp3 regulatory T cells by low-dose cyclophosphamide is explained by reduced intracellular ATP levels

22 November 2024

42

1 reference

https://api.crossref.org/works/10.1016/J.COI.2010.12.010

CD4 FOXP3 regulatory T cell depletion by low-dose cyclophosphamide prevents recurrence in patients with large condylomata acuminata after laser therapy

22 November 2024

43

1 reference

https://api.crossref.org/works/10.1016/J.COI.2010.12.010

PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors

22 November 2024

44

1 reference

https://api.crossref.org/works/10.1016/J.COI.2010.12.010

Combining T-cell vaccination and application of agonistic anti-GITR mAb (DTA-1) induces complete eradication of HPV oncogene expressing tumors in mice

22 November 2024

45

1 reference

https://api.crossref.org/works/10.1016/J.COI.2010.12.010

Costimulation as a platform for the development of vaccines: a peptide-based vaccine containing a novel form of 4-1BB ligand eradicates established tumors

22 November 2024

46

1 reference

https://api.crossref.org/works/10.1016/J.COI.2010.12.010

Pretreatment with cisplatin enhances E7-specific CD8 T-Cell-mediated antitumor immunity induced by DNA vaccination

22 November 2024

47

1 reference

https://api.crossref.org/works/10.1016/J.COI.2010.12.010

Adoptive transfer of human papillomavirus E7-specific CTL enhances tumor chemoresponse through the perforin/granzyme-mediated pathway

22 November 2024

48

1 reference

https://api.crossref.org/works/10.1016/J.COI.2010.12.010

Immune response during therapy with cisplatin or radiation for human papillomavirus-related head and neck cancer

22 November 2024

49

1 reference

https://api.crossref.org/works/10.1016/J.COI.2010.12.010

Low-dose radiation enhances therapeutic HPV DNA vaccination in tumor-bearing hosts

22 November 2024

50

1 reference

https://api.crossref.org/works/10.1016/J.COI.2010.12.010

De novo generation and enhanced suppression of human CD4 CD25 regulatory T cells by retinoic acid

22 November 2024

51

1 reference

https://api.crossref.org/works/10.1016/J.COI.2010.12.010

A tritherapy combination of a fusion protein vaccine with immune-modulating doses of sequential chemotherapies in an optimized regimen completely eradicates large tumors in mice

22 November 2024

52

1 reference

https://api.crossref.org/works/10.1016/J.COI.2010.12.010

Cycloxygenase-2 inhibition augments the efficacy of a cancer vaccine

22 November 2024

53

1 reference

https://api.crossref.org/works/10.1016/J.COI.2010.12.010

Systemic blockade of transforming growth factor-beta signaling augments the efficacy of immunogene therapy

22 November 2024

54

1 reference

https://api.crossref.org/works/10.1016/J.COI.2010.12.010

22 November 2024

Identifiers

1 reference

24 August 2017

1 reference